Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing

Jihoon G. Yoon, Seung Hwan Song, Sungkyoung Choi, Jaeseong Oh, In Jin Jang, Young Jin Kim, Sanghoon Moon, Bong Jo Kim, Yuri Cho, Hyo Kee Kim, Sangil Min, Jongwon Ha, Ho Sik Shin, Chul Woo Yang, Hye Eun Yoon, Jaeseok Yang, Min Goo Lee, Jae Berm Park, Myoung Soo Kim

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Background. Tacrolimus (TAC) is an immunosuppressant widely prescribed following an allogenic organ transplant. Due to wide interindividual pharmacokinetic (PK) variability, optimizing TAC dosing based on genetic factors is required to minimize nephrotoxicity and acute rejections. Methods. We enrolled 1133 participants receiving TAC from 4 cohorts, consisting of 3 with kidney transplant recipients and 1 with healthy males from clinical trials. The effects of clinical factors were estimated to appropriately control confounding variables. A genome-wide association study, haplotype analysis, and a gene-based association test were conducted using the Korea Biobank Array or targeted sequencing for 114 pharmacogenes. Results. Genome-wide association study verified that CYP3A5∗3 is the only common variant associated with TAC PK variability in Koreans. We detected several CYP3A5 and CYP3A4 rare variants that could potentially affect TAC metabolism. The haplotype structure of CYP3A5 stratified by CYP3A5∗3 was a significant factor for CYP3A5 rare variant interpretation. CYP3A4 rare variant carriers among CYP3A5 intermediate metabolizers displayed higher TAC trough levels. Gene-based association tests in the 61 absorption, distribution, metabolism, and excretion genes revealed that CYP1A1 are associated with additional TAC PK variability: CYP1A1 rare variant carriers among CYP3A5 poor metabolizers showed lower TAC trough levels than the noncarrier controls. Conclusions. Our study demonstrates that rare variant profiling of CYP3A5 and CYP3A4, combined with the haplotype structures of CYP3A locus, provide additive value for personalized TAC dosing. We also identified a novel association between CYP1A1 rare variants and TAC PK variability in the CYP3A5 nonexpressers that needs to be further investigated.

Original languageEnglish
Pages (from-to)2213-2225
Number of pages13
Issue number10
StateAccepted/In press - 2021

Bibliographical note

Funding Information:
This research was supported by a grant (HI15C1543) from the Korea Health Technology R&D Project administered by the Korea Health Industry Development Institute (KHIDI) and funded by the Ministry of Health & Welfare, Republic of Korea. This work was also supported by a grant from the National Research Foundation of Korea (NRF), which in turn is funded by the Korean government (NRF-2013R1A3A2042197), and additional funding (2014-ER6301-00, 2014-ER6301-01, 2014-ER6301-02, 2017-ER6301-00, 2016-NI73001-02, and 2019-NG-053-00) came from the Research of Korea Centers for Disease Control and Prevention.

Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.


Dive into the research topics of 'Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing'. Together they form a unique fingerprint.

Cite this